抗淀粉样蛋白免疫治疗的血管理神经病学考量:美国心脏协会科学咨询
该科学咨询由美国心脏协会发布,针对早期阿尔茨海默病抗淀粉样蛋白免疫治疗可能引发的淀粉样蛋白相关影像学异常(脑水肿或出血),梳理了脑血管病患者接受抗体治疗的筛选、抗栓治疗与溶栓的安全性、以及严重影像学异常的管理等关键问题,旨在为临床医生在积累更多数据期间提供决策指导。
要点
- 抗淀粉样蛋白免疫治疗可致淀粉样蛋白相关影像学异常(脑水肿或出血)。
- 需明确哪些脑血管病表现应禁止或允许抗体治疗。
- 需评估抗栓治疗者用抗体、抗体治疗者急性卒中溶栓的安全性。
核心结论
- 该科学咨询总结了指导抗淀粉样蛋白免疫治疗相关复杂决策的数据与关键考量,以帮助医学界在积累更多数据与经验期间应对这些挑战。
研究设计与样本
- 美国心脏协会发布的科学咨询,总结现有数据与关键考量以指导临床决策。
主要发现
- 靶向淀粉样蛋白β肽的抗体为早期阿尔茨海默病提供疾病修饰治疗前景,但也带来脑水肿或出血事件风险,统称为淀粉样蛋白相关影像学异常。
关键数值与推荐
- 原文未报告具体推荐条款或数值标准。
临床怎么用
- 原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibodies directed at the amyloid-β peptide offer the prospect of disease-modifying therapy for early-stage Alzheimer disease but also carry the risk of brain edema or bleeding events, collectively designated amyloid-related imaging abnormalities. Introduction of the antiamyloid immunotherapies into practice is therefore likely to present a new set of questions for clinicians treating patients with cerebrovascular disease: Which manifestations of cerebrovascular disease should preclude, or permit, antibody treatment? Is it safe to prescribe amyloid immunotherapies to individuals who require antithrombotic treatment, or to administer thrombolysis to antibody-treated individuals with acute stroke? How should severe amyloid-related imaging abnormalities be managed? This science advisory summarizes the data and key considerations to guide these challenging decisions as the medical community collects further data and experience with these groundbreaking agents.
引用
- Greenberg SM, Aparicio HJ, Furie KL, et al. Vascular Neurology Considerations for Antiamyloid Immunotherapy: A Science Advisory From the American Heart Association. Stroke. 2024. PMID: 39660440. doi:10.1161/STR.0000000000000480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。